Abstract: The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorders, such as a non-Hodgkin's lymphoma (NHL); e.g., an aggressive NHL or a relapsed and/or refractory NHL). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.

Abstract: The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.

Abstract: An ink composition for ink jet textile printing of the present disclosure contains a color material, a water-soluble organic solvent, and water, and the color material contains a color material A represented by Formula (1) below, a color material B represented by Formula (2) below, and a color material C that has a triazine structure and is different from the color material A and the color material B.

Abstract: An aqueous ink jet ink composition of the present disclosure contains a color material represented by Formula (1) below, a water-soluble organic solvent, and water. The color material represented by Formula (1) below contains two or more alkali metal ions as counterions, and the counterions include at least a sodium ion. (In Formula (1), M represents a counterion.

Abstract: An ink jet textile-printing ink composition according to the present disclosure contains an acidic dye having water solubility of 30 g/L or less at 20° C., a water-soluble organic solvent, and water, wherein a glycol-based solvent and a cyclic-amide-based solvent are contained as the water-soluble organic solvent, and the cyclic-amide-based solvent contains one or both of ?-caprolactam and N-hydroxyethyl-2-pyrrolidone.

Abstract: The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.

Abstract: An ink jet ink composition includes a coloring material, a water-soluble organic solvent, and water. The coloring material contains a compound (A) having Cr (chromium) as Me in a structure represented by formula (1) below, and a compound (B) having Co (cobalt) as Me in the structure represented by the formula (1) below, and the mass ratio of the compound (B) to the compound (A) is over 0 and 0.06 or less.

Abstract: The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.

Abstract: A compressor includes a compression mechanism, an electric motor unit, a drive shaft and a housing. A portion of the drive shaft, which is located on one side in an axial direction, is rotatably supported by a main bearing, which is formed integrally in one-piece with or is fixed to a main bearing member of the compression mechanism. Another portion of the drive shaft, which is located on another side in the axial direction, is rotatably supported by a sub-bearing, which is formed integrally in one-piece with or is fixed to an inside of a body portion of a sub-bearing member. The sub-bearing member is formed separately from the housing and is fixed to a bottom surface of a bottom portion of the housing.

Abstract: An ink jet ink composition contains a color material, an organic solvent, and water. The ink jet ink composition contains N-hydroxyethylpyrrolidone and N-vinyl-2-pyrrolidone as the organic solvent.

Abstract: An ink jet ink composition contains at least one dye, an organic solvent, and water. The ink jet ink composition contains, as the organic solvent, at least one selected from the group consisting of 1-(2-hydroxyethyl)-2-pyrrolidone and 2-pyrrolidone and the compound represented by formula (1) below.

Abstract: An ink jet printing penetrant includes a lactam compound having a hydroxy group and a glycol having a vapor pressure of 1.0 to 20.0 Pa at 20° C., a content of the lactam compound with respect to a total mass of the ink jet printing penetrant is 15 to 25 percent by mass, and a content of the glycol with respect to a total mass of the lactam compound is 0.8 to 3.0 on a mass ratio basis.

Abstract: A textile printing method for printing on a fabric, the fabric being a nonwoven fabric containing synthetic fibers. includes a first adhering step of adhering to the fabric by ejecting a dyeing ink by an ink jet method, and a second adhering step of adhering a non-dyeing ink to the fabric. The dyeing ink contains a disperse dye, a water-soluble organic solvent, and water, and the non-dyeing ink contains a water-soluble organic solvent and water. The water-soluble organic solvent contained in the non-dyeing ink contains a glycol-based organic solvent having a HSP value of 13.6 or more, and the content of the glycol-based organic solvent is 80% by mass or more relative to the total amount of the organic solvent contained in the non-dyeing ink. The adhesion position of the dyeing ink and the adhesion position of the non-dyeing ink are at least partially overlapped each other.

Abstract: An ink composition for ink jet textile printing according to the present disclosure contains a specific acidic dye being at least one selected from the group consisting of C.I. Acid Blue 112 and C.I. Acid Blue 140, a water-soluble organic solvent, and water. A glycol-based solvent and a cyclic amide-based solvent are contained as the water-soluble organic solvent. The cyclic amide-based solvent contains at least either ?-caprolactam or N-hydroxyethyl-2-pyrrolidone. The content of the glycol-based solvent is 10.0% by mass or more.

Abstract: Provided is an ink composition for ink jet printing containing a coloring material, a water-soluble organic solvent, and water. The coloring material contains a compound A represented by Formula (1) and a compound B represented by Formula (2) and a mass ratio (a/b) of a content a of the compound A to a content b of the compound B is 1.0 or more and 99 or less.

Abstract: An ink jet ink composition includes a coloring material, a water-soluble organic solvent, and water. The coloring material contains a compound (A) having Cr (chromium) as Me in a structure represented by formula (1) below, and a compound (B) having Co (cobalt) as Me in the structure represented by the formula (1) below, and the mass ratio of the compound (B) to the compound (A) is over 0 and 0.06 or less.

Abstract: An ink jet textile-printing ink composition according to the present disclosure contains an acidic dye having water solubility of 30 g/L or less at 20° C., a water-soluble organic solvent, and water, wherein a glycol-based solvent and a cyclic-amide-based solvent are contained as the water-soluble organic solvent, and the cyclic-amide-based solvent contains one or both of ?-caprolactam and N-hydroxyethyl-2-pyrrolidone.

Abstract: The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.

Abstract: A compressor includes a compression mechanism, an electric motor unit, a drive shaft and a housing. A portion of the drive shaft, which is located on one side in an axial direction, is rotatably supported by a main bearing, which is formed integrally in one-piece with or is fixed to a main bearing member of the compression mechanism. Another portion of the drive shaft, which is located on another side in the axial direction, is rotatably supported by a sub-bearing, which is formed integrally in one-piece with or is fixed to an inside of a body portion of a sub-bearing member. The sub-bearing member is formed separately from the housing and is fixed to a bottom surface of a bottom portion of the housing.

Abstract: The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.